NCT01977781View on ClinicalTrials.gov

Safety and Efficacy of Topical Tacrolimus 0.05% in the Treatment of Ocular Graft-Versus-Host Disease

PHASE1CompletedINTERVENTIONAL
Enrollment

40

Participants

Timeline

Start Date

December 31, 2013

Primary Completion Date

September 30, 2014

Study Completion Date

September 30, 2014

Conditions
Ocular GVHD
Interventions
DRUG

Tacrolimus

Topical bilateral application of 0.05% Tacrolimus BID for 10 weeks

DRUG

Methylprednisolone Sodium Succinate

Topical bilateral application of 0.5% methylprednisolone sodium succinate BID for 10 weeks

Trial Locations (1)

02114

Massachusetts Eye and Ear Infirmary, Boston

All Listed Sponsors
lead

Massachusetts Eye and Ear Infirmary

OTHER

NCT01977781 - Safety and Efficacy of Topical Tacrolimus 0.05% in the Treatment of Ocular Graft-Versus-Host Disease | Biotech Hunter | Biotech Hunter